QAX028

QAX028 is an investigational inhaled small molecule drug developed by Novartis as a long-acting muscarinic receptor antagonist (LAMA) for the treatment of chronic obstructive pulmonary disease (COPD). It was designed to act as a bronchodilator by blocking muscarinic receptors in the airways, thereby reducing bronchoconstriction and improving airflow in COPD patients. Clinical development included phase 1 and phase 2 trials comparing its efficacy and safety to tiotropium and placebo in mild-to-moderate COPD patients. The program was discontinued after phase 2 trials, with no further development reported[1][2][4][7].